NovaBay Pharmaceuticals to Hold Third Quarter 2020 Conference Call on November 12
October 30 2020 - 5:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it
will report financial results for the three and nine months ended
September 30, 2020 after market close on Thursday, November 12,
2020 and will hold an investment community conference call that day
at 4:30 p.m. Eastern time.
“I’m excited to share details on a very successful quarter. In
the third quarter of this year we increased our cash position, came
back into compliance with the NYSE American continued listing
requirements, and sold a record number of Avenova units,” said
Justin Hall, NovaBay CEO. “In addition to those major
accomplishments, we continue to work diligently in fulfilling
information requests from the EPA for inclusion of Avenova on the
list of approved disinfectants that kill the SARS-CoV-2 virus, and
with the FDA to secure EUA for the antibody test kit.”
Date/Time:
Thursday, November 12, 4:30 p.m. ET
/ 1:30 p.m. PT
Pre-Registration:
Participants can pre-register for the
conference call using the following link:
http://www.directeventreg.com/registration/8439986
Callers who pre-register will be
given a conference passcode and unique PIN to gain immediate access
to the call and bypass the live operator. Participants may
pre-register at any time, including up to and after the call start
time.
Dial In:
Those who choose not to pre-register can
access the live conference by dialing the following and requesting
the NovaBay Pharmaceuticals call:
866-677-7731 from within the U.S.
480-405-6745 from outside the U.S.
The live call also will be available at
http://novabay.com/investors/events. A replay of the call will be
available beginning two hours after its completion through 11:59
p.m. Eastern time December 3, 2020 by dialing 855-859-2056 from
within the U.S. or 404-537-3406 from outside the U.S., and entering
conference ID 8439986. The call will also be archived at
http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, CELLERX® for the aesthetic
dermatology market and NEUTROPHASE® for the wound care market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Socialize and Stay informed on
NovaBay’s progress: Like us on Facebook Follow us
on Twitter Connect with NovaBay on LinkedIn Visit
NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201030005161/en/
NovaBay Contact Justin Hall,
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024